- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03530267
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (ELDERLY)
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current trial seeks to evaluate a new treatment option for elderly / frail elderly patients with mCRC including 5-FU - better tolerated than capecitabine in the FOCUS2 study - in conjunction with aflibercept, a broad active anti-angiogenic drug within a randomized phase-II setting. Patients will be randomized using a 1:1 randomization between 5-FU / aflibercept and 5-FU / oxaliplatin using the oxaliplatin-based regimen established in FOCUS2 trial. Main goal is to estimate the 6-months PFS rate with 5-FU / Aflibercept and the safety of this regimen. The decision to use a randomized phase-II design using the "FOCUS2- FOLFOX" is based on two assumptions; (i) Bias can be better controlled by using a randomized phase-II design (ii) A clear standard regimen in frail elderly cannot be defined, but FOLFOX was superior to 5-FU alone in FOCUS2 and the patient population included in the FOCUS2 study represents the patient population scheduled to be included in the current trial.
Provided the randomized phase-II study shows adequate efficacy of 5-FU / aflibercept and a tolerable safety profile, the study will be carried on to the phase-III part of the trial. Description of the terms and conditions to expand the current trial are not part of this protocol. Briefly, a potential phase-III study should aim at showing non-inferiority of 5-FU / aflibercept regarding 6-months PFS rate as primary endpoint. This would allow to include all patients from the phase-II part in the phase-III study in order to save time and patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ralf-Dieter Hofheinz, Prof. Dr.
- Phone Number: 2855 +49621383
- Email: ralf.hofheinz@umm.de
Study Contact Backup
- Name: Claudia Pauligk, Dr.
- Phone Number: 3906 +49697601
- Email: elderly@ikf-khnw.de
Study Locations
-
-
-
Aschaffenburg, Germany, 63739
- Phase Drei
-
Bad Saarow, Germany, 15526
- Helios Klinikum Bad Saarow
-
Bayreuth, Germany, 95445
- Klinikum Bayreuth
-
Berlin, Germany, 13347
- MVZ Seestrasse
-
Bremen, Germany, 28755
- Klinikum Bremen Nord
-
Essen, Germany, 45136
- Kliniken Essen-Mitte
-
Frankfurt, Germany, 60431
- Agaplesion Markus Krankenhaus
-
Frankfurt, Germany, 60488
- Krankenhaus Nordwest GmbH
-
Garmisch-Partenkirchen, Germany, 82467
- Klinikum Garmisch-Partenkirchen Gmbh
-
Heidelberg, Germany, 69120
- Nationales Centrum für Tumorerkrankungen (NCT)
-
Karlsruhe, Germany, 76133
- Städtisches Klinikum Karlsruhe
-
Kassel, Germany, 34121
- DRK-Kliniken Nordhessen gGmbH
-
Lahr, Germany, 77933
- Ortenau Klinikum Lahr
-
Lebach, Germany, 66822
- Onkologisches Zentrum
-
Ludwigshafen, Germany, 67063
- Klinikum Ludwigshafen
-
Magdeburg, Germany, 39130
- Klinikum Magdeburg gGmbH
-
Mannheim, Germany, 68167
- Tagestherapiezentrum am ITM Universitätsmedizin Mannheim
-
Mutlangen, Germany, 73557
- Kliniken Ostalb
-
München, Germany, 81377
- Klinikum der Universität München-Großhadern
-
Neumarkt In Der Oberpfalz, Germany, 92318
- Kliniken des Landkreises Neumarkt in der Oberpfalz
-
Ravensburg, Germany, 88212
- Studienzentrum Onkologie Ravensburg
-
Stolberg, Germany, 52222
- Clinical Research Stolberg GmbH
-
Trier, Germany, 54290
- Klinikum Mutterhaus Trier
-
Tübingen, Germany, 72076
- Universitätsklinikum Tübingen
-
Wilhelmshaven, Germany, 26389
- Klinikum Wilhelmshaven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- To enter this trial the oncologist has to confirm, that the patient was in his or her opinion not a candidate for standard full-dose combination therapy. Moreover, the oncologist has to state the reason for entering the trial (Advanced age alone versus both age and frailty). As an operational definition for frailty the G8 screening tool will be used upon inclusion of the patient in a standardized manner. Briefly, G8 is an established screening tool that includes seven items from the Mini Nutritional Assessment (MNA) and an age-related item (<80, 80 to 85, or 85 years). The total score can range from 0 to 17. The result on the G8 is considered abnormal if the score is ≤14, indicating a geriatric risk profile.
- Patients have to have histologically confirmed mCRC with unidimensionally measurable inoperable advanced or metastatic disease
- ECOG performance status of 2 or better.
- Life expectancy of 3 months or longer at enrolment
- Patients >70 years with no upper age limit
- Previous adjuvant chemotherapy is allowed if completed more than 6 months before randomisation
- Previous rectal (chemo)radiotherapy is allowed if completed more than 6 months before randomisation
Hematological status:
- Neutrophils (ANC) ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL
Adequate renal function:
• Serum creatinine level ≤ 1.5 x upper limit normal (ULN)
Adequate liver function:
- Serum bilirubin ≤ 1.5 x upper limit normal (ULN)
- Alkaline phosphatase ≤ 2.5 x ULN (unless liver metastases are present, then < 5 x ULN in that case)
- AST and ALT < 3 x ULN (unless liver metastases are present then < 5 x ULN in that case)
- Proteinuria < 2+ (dipstick urinalysis) or ≤ 1 g/24hour
- Signed and dated informed consent, and willing and able to comply with protocol requirements
- Regular follow-up feasible
- Male patients with a partner of childbearing potential must agree to use effective contraception (Pearl Index < 1) during the course of the trial and at least 3 months after last administration of the study drug.
Exclusion Criteria:
- Prior systemic chemotherapy for mCRC
Other concomitant or previous malignancy, except:
- Adequately treated in-situ carcinoma of the uterine cervix
- Basal or squamous cell carcinoma of the skin
- Cancer in complete remission for > 5 years
- Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 Days
- History or evidence upon physical examination of CNS metastasis unless adequately treated (irradiation and no seizure with appropriate treatment)
- Uncontrolled hypercalcemia
- Pre-existing peripheral neuropathy (NCI grade ≥2)
- Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
- Treatment with any other investigational medicinal product within 28 days prior to study entry.
Significant cardiovascular disease:
- Cardiovascular accident or myocardial infarction or unstable angina ≤6 months before start of study treatment
- Severe cardiac arrhythmia
- New York Heart Association grade ≥2 congestive heart failure
- Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy.
- History of stroke or transient ischemic attack ≤6 months before start of study treatment
- Coronary/peripheral artery bypass graft ≤6 months before start of study treatment.
- Deep vein thrombosis or thromboembolic events ≤1 month before start of study treatment
- Patients with known allergy to any excipient to study drugs,
- Any of the following within 3 months prior to randomization: Grade 3-4 gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.
- Bowel obstruction.
- Treatment with CYP3A4 inducers unless discontinued > 7 days prior to randomization
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Involvement in the planning and/or conduct of the study (applies to both Sanofi staff and/or staff of sponsor and study site)
- Patient who might be dependent on the sponsor, site or the investigator
- Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A (mFOLFOX7)
Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15). This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study. |
Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
|
Experimental: Arm B (Aflibercept + mLV5FU2)
Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15). The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7. |
Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 6 months
|
Rate of patients free of progression
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Dose intensities of study medication
Time Frame: 6 months
|
As calculated over the whole treatment duration and summarized descriptively by summary statistics.
|
6 months
|
Safety: Adverse events (AE)
Time Frame: 7 months
|
AE's will be summarized by presenting the number and percentages of patients having any AE
|
7 months
|
Safety: Dose modification of study drug due to adverse events
Time Frame: 6 months
|
Dose modifications, including discontinuations, will be summarized by presenting the number and percentages of patients having any dose modification
|
6 months
|
Safety: Rate of treatment discontinuation due to toxicitiy
Time Frame: 6 months
|
Rate of treatment discontinuations during the study
|
6 months
|
Safety: Laboratory abnormalities
Time Frame: 6 months
|
Summary of lab abnormalities as assessed in the documentation
|
6 months
|
Efficacy: Response rates
Time Frame: 2 years
|
As measured by RECIST criteria v. 1.1
|
2 years
|
Efficacy: Overall survival (OS)
Time Frame: 2 years
|
OS according to Kaplan-Meier
|
2 years
|
Efficacy: PFS
Time Frame: 2 years
|
PFS according to Kaplan-Meier
|
2 years
|
Patient reported outcomes (PRO): Quality of life
Time Frame: 6 months
|
Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT.
|
6 months
|
PRO: Geriatric assessment
Time Frame: 6 months
|
Geriatric assessment as measured by using G8, ADL and IADL
|
6 months
|
PRO: Overall treatment utility
Time Frame: 6 months
|
Overall treatment utility is evaluated according to the principles used in the FOCUS2 trial.
Cf.
Seymour et al.
Geriatric oncol 2013.
|
6 months
|
Collaborators and Investigators
Investigators
- Study Chair: Salah-Eddin Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
Other Study ID Numbers
- ELDERLY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC...United States
Clinical Trials on mFOLFOX7
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingStage III Hepatocellular Cancer (CNLC Staging)China
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; Curis, Inc.RecruitingStomach Cancer | Gastric Cancer | Esophageal Cancer | Gastroesophageal Junction Cancer | Esophagus CancerUnited States
-
Sun Yat-sen UniversityXiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaboratorsRecruitingUnresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC StageChina